Neurocrine Biosciences, Inc.

NASDAQ:NBIX

109.07 (USD) • At close March 12, 2025
Bedrijfsnaam Neurocrine Biosciences, Inc.
Symbool NBIX
Munteenheid USD
Prijs 108.99
Beurswaarde 10,866,684,465
Dividendpercentage 0%
52-weken bereik 105.18 - 157.98
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Dr. Kevin C. Gorman Ph.D.
Website https://www.neurocrine.com

An error occurred while fetching data.

Over Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive

Vergelijkbare Aandelen

DENTSPLY SIRONA Inc. logo

DENTSPLY SIRONA Inc.

XRAY

15 USD

Repligen Corporation logo

Repligen Corporation

RGEN

142.44 USD

Exact Sciences Corporation logo

Exact Sciences Corporation

EXAS

43.04 USD

Bruker Corporation logo

Bruker Corporation

BRKR

44.97 USD

Maravai LifeSciences Holdings, Inc. logo

Maravai LifeSciences Holdings, Inc.

MRVI

2.42 USD

NovoCure Limited logo

NovoCure Limited

NVCR

20.06 USD

Masimo Corporation logo

Masimo Corporation

MASI

165.69 USD

Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc

JAZZ

136.05 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)